Nigral Tau pathology and striatal amyloid-β deposition does not correlate with striatal dopamine deficit in Alzheimer's disease.
Extrapyramidal symptoms may appear in Alzheimer's disease (AD). In the present study, using morphometric immunohistochemistry in 34 cases with AD-related pathology, we evaluated whether nigral burden of tau pathology or striatal burden of amyloid-β deposition correlates with dopamine transporter (DAT) expression in the striatum. Our observations show a lack of correlation between these variables and support the notion that lower striatal DAT expression in AD patients suggests concomitant nigral α-synuclein pathology. Extrapyramidal symptoms may have a complex background in AD.
Institute of Neurology, Medical University of Vienna, AKH 4J, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Tabea H
TH
Schauer
Maximilian
M
Lochner
Gabor G
GG
Kovacs
D000368:Aged; D000544:Alzheimer Disease / Q000378:metabolism* / Q000473:pathology*; D016229:Amyloid beta-Peptides / Q000378:metabolism; D001344:Autopsy; D003342:Corpus Striatum / Q000378:metabolism / Q000473:pathology*; D004298:Dopamine / Q000378:metabolism*; D050483:Dopamine Plasma Membrane Transport Proteins / Q000096:biosynthesis; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007231:Infant, Newborn; D008297:Male; D013378:Substantia Nigra / Q000378:metabolism / Q000473:pathology*; D016875:tau Proteins / Q000378:metabolism
D016229:Amyloid beta-Peptides; D050483:Dopamine Plasma Membrane Transport Proteins; D016875:tau Proteins; D004298:Dopamine